NREP
NEW REPRESENTATIVE AT IB RECEIVED
02/04/2026
Voltar para busca
Dado oficial do USPTO
MAGLUMI
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
58
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 10
Data de depósito
17/07/2013
Data de registro
10/02/2015
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
19/05/2025
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
706
Cadastro oficial
Principal Register
Código do desenho
5
Tipo de titular
99
Localização do titular
Shenzhen, Guangdong, CN
Examinador
BRADLEY, EVELYN
Localização atual
Historical data usage
Descrição da marca
The mark consists of the stylized words "MAGLUMI".
Titulares e representantes
Titulares
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.
Representantes
Nazly Aileen Bayramoglu Bayramoglu Law Offices LLC
Classificação técnica
Classes Nice
Classe 5Classe 10
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Drugs for medical purposes for treatment of tumorsthyroid diseaseglycometabolism diseasebone metabolic diseasegonad diseasekidney diseasecardiovascular diseasehepatic fibrosisanemiainflammation diseaseshepatitis diseaseEpstein-Barr (EB) viruseshormonal diseasesTORCH infections and immunoglobulin disease; medicated serums for invitro diagnosis and treatment; medicated serums for in-vivo diagnosis and treatment; serotherapeutic medicines; cultures of microorganisms for medical and veterinary use; biological preparations for pharmaceutical purposes for treatment of tumorsthyroid diseaseglycometabolism diseasebone metabolic diseasegonad diseasekidney diseasecardiovascular diseasehepatic fibrosisanemiainflammation diseaseshepatitis diseaseEpstein-Barr (EB) viruseshormonal diseasesTORCH infections and immunoglobulin diseases; chemical preparations for pharmaceutical purposesfor diagnosis or treatment of tumorsthyroid diseaseglycometabolism diseasebone metabolic diseasegonad diseasekidney diseasecardiovascular diseasehepatic fibrosisanemiainflammation diseaseshepatitis diseaseEpstein-Barr (EB) viruseshormonal diseasesTORCH infections and immunoglobulin diseases; Diagnostic preparations for medical purposesfor diagnosing or detecting tumorsthyroid diseaseglycometabolism diseasebone metabolic diseasegonad diseasekidney diseasecardiovascular diseasehepatic fibrosisanemiainflammation diseaseshepatitis diseaseEpstein-Barr (EB) viruseshormonal diseasesTORCH infections and immunoglobulin diseases; enzymes for medical purposes; enzyme preparations for medical purposes; chemical preparations for the diagnosis of pregnancy
Classe 10
Blood testing apparatus; massage apparatus; apparatus for use in medical analysismedical analyzer for analysis of blood samplesbody fluids and body tissue samples; testing apparatus for medical purposesmedical testing instrument for testing blood samplesbody fluids and body tissue samples; diagnostic apparatus for medical purposesmedical diagnostic analyzer for analyzing blood samplesbody fluids and body tissue samples; radiotherapy apparatus; ultrasonic devices and parts thereof for medical useclinical ultrasonic diagnostic apparatus and parts thereof ; artificial limbs; multifunction corsets for medical purposediagnosis and therapeutic corsets for medical purpose; suture materials
Publicações
Histórico de despachos e eventos da marca no USPTO.
58 publicações encontradas
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
19/01/2026
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
19/05/2025
71AG
REGISTERED-SEC.71 ACCEPTED
19/05/2025
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
19/05/2025
ES71
TEAS SECTION 71 RECEIVED
24/01/2025
REM4
COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
10/02/2024
RNWL
INTERNATIONAL REGISTRATION RENEWED
12/05/2023
INNP
PARTIAL INVALIDATION PROCESSED BY THE IB
12/04/2023
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
22/02/2023
XXCR
GENERIC MADRID TRANSACTION CREATED
22/02/2023
INPR
PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
02/01/2023
NA71
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
02/05/2022
71AG
REGISTERED-SEC.71 ACCEPTED
02/05/2022
EROP
TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED
19/11/2021
PR71
POST REGISTRATION ACTION MAILED - SEC.71
27/10/2021
PR71
POST REGISTRATION ACTION MAILED - SEC.71
25/10/2021
REIN
REINSTATED
25/10/2021
NC71
NOTICE OF CANCELLATION SEC. 71 E-MAILED
16/10/2021
C71T
CANCELLED SECTION 71
15/10/2021
PR71
POST REGISTRATION ACTION MAILED - SEC.71
11/03/2021
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
04/03/2021
ES71
TEAS SECTION 71 RECEIVED
07/02/2021
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
20/02/2020
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
26/11/2015
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
27/06/2015
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/06/2015
FIMP
FINAL DISPOSITION PROCESSED
11/06/2015
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/05/2015
R.PR
REGISTERED-PRINCIPAL REGISTER
10/02/2015
CORN
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
13/01/2015
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
03/01/2015
PUBO
PUBLISHED FOR OPPOSITION
25/11/2014
NPUB
NOTICE OF PUBLICATION
05/11/2014
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
23/10/2014
CNEA
EXAMINERS AMENDMENT MAILED
22/10/2014
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
22/10/2014
XAEC
EXAMINER'S AMENDMENT ENTERED
22/10/2014
CNEA
EXAMINERS AMENDMENT -WRITTEN
22/10/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
14/10/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/10/2014
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
13/10/2014
CNFR
FINAL REFUSAL MAILED
27/05/2014
CNFR
FINAL REFUSAL WRITTEN
26/05/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
17/04/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
17/04/2014
ALIE
ASSIGNED TO LIE
08/04/2014
ALIE
ASSIGNED TO LIE
28/03/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
17/03/2014
RFNT
REFUSAL PROCESSED BY IB
17/01/2014
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
30/12/2013
RFRR
REFUSAL PROCESSED BY MPU
30/12/2013
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
21/12/2013
CNRT
NON-FINAL ACTION WRITTEN
20/12/2013
MAFR
APPLICATION FILING RECEIPT MAILED
18/12/2013
DOCK
ASSIGNED TO EXAMINER
14/12/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
14/12/2013
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/12/2013
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace MAGLUMI ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.